Skip to main content
SPECIALITY MEDICINES LIMITED logo

SPECIALITY MEDICINES LIMITED — Investor Relations & Filings

Ticker · 544738 ISIN · INE0R0M01014 BSE.NS Manufacturing
Open in API
Filings indexed 4 across all filing types
Latest filing 2026-05-28 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS 544738

About SPECIALITY MEDICINES LIMITED

https://www.specialitymedicine.com

Speciality Medicines Limited is a pharmaceutical enterprise focused on the formulation, marketing, and distribution of specialized therapeutic products. The company operates across diverse medical segments, including critical care, oncology, nephrology, and immunology. Its core business activities involve the procurement and supply of high-quality medicinal formulations designed to address complex clinical requirements. Speciality Medicines Limited emphasizes the provision of niche pharmaceutical solutions through a structured distribution network and strategic collaborations with healthcare institutions. The organization maintains a commitment to quality assurance and regulatory compliance, ensuring the availability of essential treatments for chronic and acute conditions. Its portfolio includes a variety of dosage forms, such as injectables and oral solids, aimed at improving patient outcomes in specialized medical fields.

Recent filings

Filing Released Lang Actions
We hereby submit Financial Results for the Half Year and Year ended March 31, 2026.
Interim / Quarterly Report Classification · 85% confidence The document is a stock‐exchange filing titled “Outcome of Board meeting” providing Audited Standalone Financial Results for the half‐year and full year ended March 31, 2026, along with detailed financial statements (income statement, assets & liabilities) and notes. It contains comprehensive actual financial data for a period shorter than a full fiscal year (the half‐year results), not merely summary highlights, and is not a full Annual Report. Hence, it fits the Interim/Quarterly Report (IR) category. FY 2026
2026-05-28 English
We hereby submit the Outcome of Board Meeting held On May 28, 2026.
Interim / Quarterly Report Classification · 85% confidence The document is the full set of audited standalone financial results for the half‐year and full year ended March 31, 2026 (including P&L, assets & liabilities and notes), filed after a board meeting. It is not an earnings summary (ER) nor a full annual report (10-K), but a substantive interim/half‐year financial report under SEBI regulations. Therefore it best fits the Interim / Quarterly Report category. FY 2026
2026-05-28 English
Speciality Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve 1. Audited Standalone ....
Regulatory Filings Classification · 75% confidence The document is a formal intimation under Regulation 29 of SEBI LODR announcing the date of the Board of Directors meeting to consider and approve the audited financial results. It does not contain any financial statements or substantive data itself, nor is it announcing the publication of a report. It is a regulatory disclosure/notice to the exchange, so it falls under general Regulatory Filings (RNS).
2026-05-21 English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Niraj Shah
Major Shareholding Notification Classification · 95% confidence The document is a formal disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (Regulation 29(1)), detailing Niraj Rajnikant Shah’s acquisition of 6.22% of Speciality Medicines Limited’s share capital. It reports crossing a significant shareholding threshold and provides shareholding details pre- and post-acquisition. This matches the definition of a Major Shareholding Notification.
2026-05-19 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.